Woman Who Feels No Pain May Mean a Major Scientific Gain

Michael Vlessides

April 03, 2019

A Scottish woman who feels virtually no pain has left British researchers not only astounded but looking for a way to harness her previously unidentified genetic mutation to guide new treatments for a range of conditions.

The woman's genetic microdeletion in dorsal root ganglia and brain-expressed pseudogene — which the researchers called FAAH-OUT — is consistent with a phenotype resulting from enhanced endocannabinoid signaling and a loss of function of fatty acid amide hydrolase (FAAH).

"We have identified a novel cause of human pain insensitivity in a patient with a non-anxious, happy, talkative disposition," study author James Cox, PhD, told Medscape Medical News.

"FAAH was already a heavily studied gene in the pain and anxiety fields, and FAAH inhibitors have been tested in clinical trials for pain," added Cox, senior lecturer at University College London in England.

"This case report is the first patient with a hypomorphic mutation in the FAAH gene and a microdeletion in a novel downstream gene, which we have called FAAH-OUT. FAAH-OUT is exciting as it was previously unknown and encodes a long non-coding RNA and is a potential new analgesic drug target in itself."

The study was published online February 22 in the British Journal of Anesthesia.

Junk Gene No More

As surprising as the circumstances were to investigators, the FAAH gene is far from obscure in pain research. Indeed, it has previously been found to be involved in endocannabinoid signaling central to pain sensation, mood, and memory. Nevertheless, FAAH-OUT was previously assumed to be a nonfunctional "junk" gene.

Jo Cameron, 71 (Peter Jolly/Shutterstock)

However, such is not the experience of 71-year-old Jo Cameron, who has lived a virtually pain-free life…and notoriety. That began to change 6 years ago, when Cameron sought treatment for an issue with her hip. As it turns out, she was suffering from severe joint degeneration, but felt no pain. A year later, she underwent otherwise painful surgery on her hand. Once again, she felt no pain.

This has been a common occurrence throughout her life. She has often experienced burns and cuts without pain, occasionally not realizing she was burning herself until she smelled her own flesh. She has never needed painkillers after surgery, and often found that her wounds healed quickly, with little or no residual scar.

Yet as commonplace as this may have been for Cameron, it came as quite as shock to study coauthor Devjit Srivastava, MD, MBBS, from Raigmore Hospital in Inverness, Scotland, who first saw Cameron, and subsequently referred her to pain geneticists at University College London and the University of Oxford.

Quantitative sensory testing at these institutions confirmed Cameron's hyposensitivity to noxious heat in both her hands and feet. Genetic analyses were then performed.

The scientists isolated genomic DNA from Cameron, her two children, and her mother for exome sequencing. After filtering variants, they identified four candidate mutations, though none were considered likely to be causal for the phenotype.

The investigators then broadened the genetic analyses and searched for cytogenetic copy number changes across the genome.

Two Notable Mutations

These tests revealed two notable mutations. Of these, one was a microdeletion in a pseudogene. Although the microdeletion had been briefly annotated in previous literature, Cox and his team described it for the first time, calling it FAAH-OUT. Cameron also had a mutation in a neighboring gene that controls the FAAH enzyme.

Interestingly, while Cameron's unaffected mother and daughter did not carry the microdeletion, her son — who also has some pain-sensitivity deficits — was heterozygous for it.

The investigators then explored ways in which the microdeletion could be pathogenic. Tissue expression analyses showed that FAAH-OUT was expressed in a wide range of tissues, including fetal and adult brain, as well as dorsal root ganglia.

Further tests by collaborators at the University of Calgary in Canada, revealed elevated blood levels of neurotransmitters that are normally degraded by FAAH. This, the scientists said, provides further evidence for a loss of FAAH function.

Although Cameron's insensitivity to pain is certainly rare, the researchers believe it may be possible that other people are living with the same mutation. Nevertheless, they continue to conduct further tests on Cameron's cell samples to help better understand her novel pseudogene.

Such tests, they hope, may one day open the door to gene therapy techniques that contribute to clinical research for acute postoperative pain and anxiety as well as chronic pain, posttraumatic stress disorder (PTSD), and even wound healing.

"We would be delighted if these findings would lead to better therapies for the millions of people living in chronic pain," Cox said. "With the devastating opioid crisis, there is a real need for new painkillers. In addition, a drug targeting FAAH/FAAH-OUT has the potential to help people with anxiety disorders, PTSD, and also help in wound healing."

Implications for Pain Med Development?

Commenting on the case and related findings for Medscape Medical News, Frances M.K. Williams, PhD, who was not involved in the study, said there are many examples where pain-related genetic mutations have been identified in families.

"This case is unusual because the other families have shown mutations in genes coding for ion channels, which start the electrical impulses in nerves, carrying the message of touch or pain to the brain," said Williams, professor of genomic epidemiology and honorary consultant rheumatologist at King's College London in England.

Cameron's genetic profile sheds light on past — and future — efforts to develop analgesic medications based on such mutations, Williams said.

"The protein made by the FAAH gene — fatty acid amide hydrolase — has already been targeted as a possible painkiller, without much success," she said. "It is an enzyme that breaks down the cannabinoids made naturally in the body, so was an obvious choice to try and block.

"More interesting is the FAAH-OUT pseudogene. This is the first time it has been linked to pain, but we don't have much idea what pseudogenes do. It seems that the combination of two different types of genetic change in this lady leads to a very pain-resistant phenotype, as can be seen in her family, as no one else has the same two mutations that she has."

The authors have disclosed no relevant financial relationships.

The study was funded by Medical Research Council, Wellcome Trust, Alzheimer's Society, University of Cambridge Academic Foundation Programme, Molecular Nociception Group, National Institutes of Health, Ruth L. Kirschstein Institutional National Research Service Award, and Canadian Institutes of Health Research.

Br J Anaesth. Published online February 22, 2019. Full text

For more Medscape Neurology news, join us on Facebook and Twitter


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.